| __timestamp | Amphastar Pharmaceuticals, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 21954000000 |
| Thursday, January 1, 2015 | 46974000 | 21203000000 |
| Friday, January 1, 2016 | 47298000 | 19945000000 |
| Sunday, January 1, 2017 | 50918000 | 21420000000 |
| Monday, January 1, 2018 | 58044000 | 22540000000 |
| Tuesday, January 1, 2019 | 63109000 | 22178000000 |
| Wednesday, January 1, 2020 | 65157000 | 22084000000 |
| Friday, January 1, 2021 | 68920000 | 20118000000 |
| Saturday, January 1, 2022 | 66592000 | 19046000000 |
| Sunday, January 1, 2023 | 80393000 | 20112000000 |
| Monday, January 1, 2024 | 21969000000 |
Igniting the spark of knowledge
In the world of pharmaceuticals, understanding spending patterns can reveal much about a company's strategic priorities. Over the past decade, Johnson & Johnson and Amphastar Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Johnson & Johnson's SG&A expenses have fluctuated, peaking in 2018 and then declining by approximately 15% by 2022. In contrast, Amphastar Pharmaceuticals has steadily increased its SG&A spending by nearly 100% over the same period, indicating a robust expansion strategy. This divergence highlights Johnson & Johnson's focus on efficiency and cost management, while Amphastar appears to be investing heavily in growth and market penetration. These insights provide a window into the strategic directions of these industry players, offering valuable lessons for investors and competitors alike.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Selling, General, and Administrative Costs: Johnson & Johnson vs Verona Pharma plc
Johnson & Johnson or Merus N.V.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Breaking Down SG&A Expenses: Johnson & Johnson vs Galapagos NV
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Merus N.V. or Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE